Cargando…

Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors

Background. Three nomogram models for early stage uterine cervical cancer have been developed (KROG 13-03 for overall survival [OS], SNUH/AMC for disease-free survival [DFS], and KROG 12-08 for distant metastases-free survival [DMFS]) after radical hysterectomy (RH) and pelvic lymph node dissection...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Won Sup, Yang, Dae Sik, Lee, Jung Ae, Lee, Nam Kwon, Park, Young Je, Kim, Chul Yong, Lee, Nak Woo, Hong, Jin Hwa, Lee, Jae Kwan, Song, Jae Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425848/
https://www.ncbi.nlm.nih.gov/pubmed/28536694
http://dx.doi.org/10.1155/2017/2917925
_version_ 1783235361469628416
author Yoon, Won Sup
Yang, Dae Sik
Lee, Jung Ae
Lee, Nam Kwon
Park, Young Je
Kim, Chul Yong
Lee, Nak Woo
Hong, Jin Hwa
Lee, Jae Kwan
Song, Jae Yun
author_facet Yoon, Won Sup
Yang, Dae Sik
Lee, Jung Ae
Lee, Nam Kwon
Park, Young Je
Kim, Chul Yong
Lee, Nak Woo
Hong, Jin Hwa
Lee, Jae Kwan
Song, Jae Yun
author_sort Yoon, Won Sup
collection PubMed
description Background. Three nomogram models for early stage uterine cervical cancer have been developed (KROG 13-03 for overall survival [OS], SNUH/AMC for disease-free survival [DFS], and KROG 12-08 for distant metastases-free survival [DMFS]) after radical hysterectomy (RH) and pelvic lymph node dissection (PLND). This study aimed to validate these models using our cohort with adjuvant radiotherapy. Methods. According to the eligibility criteria of nomogram studies, patients were enrolled in Group A (N = 109) for the two KROG models (RH with PLND and whole pelvic irradiation) and Group B (N = 101) for the SNUH/AMC model (RH with PLND and squamous histology). Using Cox-regression hazard models, the prognostic factors of our cohorts were evaluated. The risk probabilities induced from published nomogram scores were calculated and the concordance indices were evaluated. Results. Group A had 88.1% 5-year OS and 86.0% 5-year DMFS. Group B had 83.0% 5-year DFS. In multivariate analyses, large tumor size for OS (HR 8.62, P < 0.001) and DMFS (HR 5.13, P = 0.003), young age (≤40 versus 41–64 years) for OS (HR 4.63, P = 0.097) and DFS (HR 3.44, P = 0.051), and multiple lymph node metastases (0 versus ≥3) for DMFS (HR 4.03, P = 0.031) and DFS (HR 3.90, P = 0.038) were significantly correlated. The concordance indices for OS, DMFS, and DFS were 0.612 (P = 0.002), 0.597 (P = 0.014), and 0.587 (P = 0.020), respectively. Conclusion. The developed nomogram models after RH and PLND are clinically useful in predicting various types of survival with significance.
format Online
Article
Text
id pubmed-5425848
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-54258482017-05-23 Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors Yoon, Won Sup Yang, Dae Sik Lee, Jung Ae Lee, Nam Kwon Park, Young Je Kim, Chul Yong Lee, Nak Woo Hong, Jin Hwa Lee, Jae Kwan Song, Jae Yun Biomed Res Int Clinical Study Background. Three nomogram models for early stage uterine cervical cancer have been developed (KROG 13-03 for overall survival [OS], SNUH/AMC for disease-free survival [DFS], and KROG 12-08 for distant metastases-free survival [DMFS]) after radical hysterectomy (RH) and pelvic lymph node dissection (PLND). This study aimed to validate these models using our cohort with adjuvant radiotherapy. Methods. According to the eligibility criteria of nomogram studies, patients were enrolled in Group A (N = 109) for the two KROG models (RH with PLND and whole pelvic irradiation) and Group B (N = 101) for the SNUH/AMC model (RH with PLND and squamous histology). Using Cox-regression hazard models, the prognostic factors of our cohorts were evaluated. The risk probabilities induced from published nomogram scores were calculated and the concordance indices were evaluated. Results. Group A had 88.1% 5-year OS and 86.0% 5-year DMFS. Group B had 83.0% 5-year DFS. In multivariate analyses, large tumor size for OS (HR 8.62, P < 0.001) and DMFS (HR 5.13, P = 0.003), young age (≤40 versus 41–64 years) for OS (HR 4.63, P = 0.097) and DFS (HR 3.44, P = 0.051), and multiple lymph node metastases (0 versus ≥3) for DMFS (HR 4.03, P = 0.031) and DFS (HR 3.90, P = 0.038) were significantly correlated. The concordance indices for OS, DMFS, and DFS were 0.612 (P = 0.002), 0.597 (P = 0.014), and 0.587 (P = 0.020), respectively. Conclusion. The developed nomogram models after RH and PLND are clinically useful in predicting various types of survival with significance. Hindawi 2017 2017-04-27 /pmc/articles/PMC5425848/ /pubmed/28536694 http://dx.doi.org/10.1155/2017/2917925 Text en Copyright © 2017 Won Sup Yoon et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Yoon, Won Sup
Yang, Dae Sik
Lee, Jung Ae
Lee, Nam Kwon
Park, Young Je
Kim, Chul Yong
Lee, Nak Woo
Hong, Jin Hwa
Lee, Jae Kwan
Song, Jae Yun
Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors
title Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors
title_full Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors
title_fullStr Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors
title_full_unstemmed Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors
title_short Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors
title_sort validation of nomograms for survival and metastases after hysterectomy and adjuvant therapy in uterine cervical cancer with risk factors
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425848/
https://www.ncbi.nlm.nih.gov/pubmed/28536694
http://dx.doi.org/10.1155/2017/2917925
work_keys_str_mv AT yoonwonsup validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors
AT yangdaesik validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors
AT leejungae validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors
AT leenamkwon validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors
AT parkyoungje validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors
AT kimchulyong validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors
AT leenakwoo validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors
AT hongjinhwa validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors
AT leejaekwan validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors
AT songjaeyun validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors